Document is current
Any future updates will be listed below
-
Authors
Xiong, Yunyun https://orcid.org/0000-0003-1353-2295
Li, Shuya https://orcid.org/0000-0002-7263-0365
Wang, Chunjuan https://orcid.org/0000-0002-1627-5004
Sun, Dapeng https://orcid.org/0000-0001-6321-5381
Li, Zixiao https://orcid.org/0000-0002-4713-5418
Gu, HongQiu https://orcid.org/0000-0003-1608-1856
Jin, Aoming https://orcid.org/0000-0002-7221-5444
Dong, Qiang
Liu, Liping
Miao, Zhongrong
Wang, Yongjun https://orcid.org/0000-0002-9976-2341
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct04516993 at ClinicalTrials.govnct04454788 at ClinicalTrials.govDocuments that mention this clinical trial
Tenecteplase Thrombolysis for Stroke up to 24 Hours After Onset With Perfusion Imaging Selection: The CHABLIS-T II Randomized Clinical Trial
https://doi.org/10.1161/strokeaha.124.048375
Tenecteplase thrombolysis for stroke up to 24 hours after onset with perfusion imaging selection: the umbrella phase IIa CHABLIS-T randomised clinical trial
https://doi.org/10.1136/svn-2023-002820
Chinese stroke association guidelines on reperfusion therapy for acute ischaemic stroke 2024
https://doi.org/10.1136/svn-2024-003977
nct05199662 at ClinicalTrials.govDocuments that mention this clinical trial
Efficacy of Tenecteplase in Large Vessel Occlusion Stroke Within 24 Hours of Symptom Onset: The ETERNAL-LVO Randomized Controlled Trial
https://doi.org/10.1161/strokeaha.125.052511
Tenecteplase thrombolysis for stroke up to 24 hours after onset with perfusion imaging selection: the umbrella phase IIa CHABLIS-T randomised clinical trial
https://doi.org/10.1136/svn-2023-002820
CHinese Acute Tissue-Based Imaging Selection for Lysis In Stroke Tenecteplase II (CHABLIS-T II): rationale and design
https://doi.org/10.1136/svn-2023-002890
Rationale and design of Tenecteplase Reperfusion Therapy in Acute Ischaemic Cerebrovascular Events III (TRACE III): a randomised, phase III, open-label, controlled trial
https://doi.org/10.1136/svn-2023-002310
Chinese stroke association guidelines on reperfusion therapy for acute ischaemic stroke 2024
https://doi.org/10.1136/svn-2024-003977
nct05105633 at ClinicalTrials.govDocuments that mention this clinical trial
Chinese stroke association guidelines on reperfusion therapy for acute ischaemic stroke 2024
https://doi.org/10.1136/svn-2024-003977
Tenecteplase: expanding horizons in thrombolytic therapy across various clinical indications
https://doi.org/10.1136/heartjnl-2024-325249
nct06196320 at ClinicalTrials.govDocuments that mention this clinical trial
Penultimate proof for posterior occlusions: a commentary on “Focused update to guidelines for endovascular therapy for emergent large vessel occlusion: basilar artery occlusion patients”
https://doi.org/10.1136/jnis-2024-021870
Chinese stroke association guidelines on reperfusion therapy for acute ischaemic stroke 2024
https://doi.org/10.1136/svn-2024-003977
Tenecteplase: expanding horizons in thrombolytic therapy across various clinical indications
https://doi.org/10.1136/heartjnl-2024-325249
Tenecteplase versus standard care in patients with acute basilar artery occlusion: a multi-centre, prospective, randomised, open-label, blinded endpoint, phase 3, controlled trial
https://doi.org/10.1136/svn-2025-004432
Documents that mention this clinical trial
30 years of thrombolysis for ischaemic stroke: expanded agents, widened windows and accelerated delivery
https://doi.org/10.1136/svn-2025-004987
Chinese stroke association guidelines on reperfusion therapy for acute ischaemic stroke 2024
https://doi.org/10.1136/svn-2024-003977
Tenecteplase: expanding horizons in thrombolytic therapy across various clinical indications
https://doi.org/10.1136/heartjnl-2024-325249
Tenecteplase versus standard care in patients with acute basilar artery occlusion: a multi-centre, prospective, randomised, open-label, blinded endpoint, phase 3, controlled trial
https://doi.org/10.1136/svn-2025-004432
-
Funding
Funding for this research was provided by:
Noncommunicable Chronic Diseases-National Science and Technology Major Project (2023ZD0505400)
Noncommunicable Chronic Diseases-National Science and Technology Major Project (2023ZD0505401)
Noncommunicable Chronic Diseases-National Science and Technology Major Project (2023ZD0505402)
Noncommunicable Chronic Diseases-National Science and Technology Major Project (2023ZD0505404)
Beijing Outstanding Young Scientist Program (JQ24058)
- License Information
